AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00760344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
Trial: NCT01857726
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transarterial chemoembolization (TACE) with adriamycin
Trial: NCT03866369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose at D-1
Trial: NCT03866369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily oral dose during 14 days
Trial: NCT03473210
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
Trial: NCT03473210
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
Trial: NCT01937169
Drug: Levodopa tablet
RxNorm normalized name: Levodopa Tablets
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01937169
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070993
Drug: creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01647542
Drug: TAK-875 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 placebo-matching tablets
Trial: NCT02638103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
Trial: NCT02294474
Drug: SAR342434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
Trial: NCT02871505
Drug: Benzathine Penicillin G
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04268537
Drug: Thymosin+standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Trial: NCT02265666
Drug: BIIL 284 BS tablet C
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01774045
Drug: PDC-1421
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01774045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03575676
Drug: SOM3355 100mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03575676
Drug: SOM3355 200mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01800708
Drug: Prednisolone syrup
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04737213
Drug: SGM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorescence guided surgery
Trial: NCT03575676
Drug: Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03714568
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
Trial: NCT00095823
Drug: Antidepressant + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Trial: NCT04282590
Drug: Placebo/TRK-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution
Trial: NCT02225821
Drug: Cephalozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Cephalozin
Trial: NCT00101335
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177253
Drug: Placebo Inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02177253
Drug: Placebo Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06250543
Drug: AbobotulinumtoxinA 300 UNT
RxNorm normalized name: abobotulinumtoxinA 300 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed
Trial: NCT06250543
Drug: IncobotulinumtoxinA 100 UNT
RxNorm normalized name: incobotulinumtoxinA 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 evenly distributed intradetrusor injections, 1 ml per site, were performed
Trial: NCT00518713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets; orally; daily for 15-18 weeks
Trial: NCT00971997
Drug: Lispro Mix 50/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
Trial: NCT00997256
Drug: Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 2 tablets / day over 3 days
Trial: NCT02470689
Drug: Diacerin cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerin tablet solubule in ultraphil cream
Trial: NCT00990951
Drug: Senna alexandrina and associations
RxNorm normalized name: Senna alexandrina seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day
Trial: NCT01888874
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0634 capsules.
Trial: NCT01888874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules.
Trial: NCT04508855
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch from direct oral anticoagulants to low molecular weight heparin
Trial: NCT00334542
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-28 weeks of simvastatin
Trial: NCT01673022
Drug: IC Green
RxNorm normalized name: ELECTRIC GREEN BARB TRANSGENIC WHOLE (GB2011 RDNA CONSTRUCT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IC Green
Trial: NCT01384812
Drug: dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection 0.4 μgr/kg/min for 25 min
Trial: NCT00519636
Drug: FPNS
RxNorm normalized name: Fluticasone Propionate and Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fluticasone propionate nasal spray
Trial: NCT00519636
Drug: placebo FFNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo nasal spray matching fluticasone furoate nasal spray
Trial: NCT00519636
Drug: placebo FPNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo nasal spray matching fluticasone propionate nasal spray
Trial: NCT00979953
Drug: ADL5747
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00979953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02847442
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
Trial: NCT02847442
Drug: levodopa/dopa decarboxylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
Trial: NCT00003458
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT01202799
Drug: 2% w/w diclofenac sodium topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% w/w diclofenac sodium topical gel
Trial: NCT01202799
Drug: 1.5% w/w diclofenac sodium topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% w/w diclofenac sodium topical solution
Trial: NCT01202799
Drug: 75 mg diclofenac sodium delayed release tablet
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg diclofenac sodium delayed release tablet
Trial: NCT04575181
Drug: NNC0268-0965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
Trial: NCT04575181
Drug: Placebo (NNC0268-0965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For s.c. injection once daily for 26 weeks
Trial: NCT04329572
Drug: Azithromycin Tablets
RxNorm normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients included in the study will receive AZT 500 mg per day for 5 days.
Trial: NCT00847626
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT00847626
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
Trial: NCT01644474
Drug: Placebo (for Ezetimibe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule orally once daily at approximately the same time of the day with or without food..
Trial: NCT02023879
Drug: Placebo (for Alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Trial: NCT02023879
Drug: Non-statin LMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.
Trial: NCT01627262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x1000mg placebo granules per day
Trial: NCT00451568
Drug: Desorelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet/day in 21 days
Trial: NCT03054337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02610075
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
Trial: NCT00887770
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 x 50mg tablet, oral, single dose
Trial: NCT00887770
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 x matched to AZD5672 50 mg tablet
Trial: NCT00887770
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 50mg tablet, oral. single dose
Trial: NCT00887770
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x matched to Moxifloxacin capsule
Trial: NCT00002838
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03214770
Drug: TheraCal
RxNorm normalized name: TheraCal D2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
Trial: NCT03214770
Drug: light-cured calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
Trial: NCT01721733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721733
Drug: EPI-743 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721733
Drug: EPI-743 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03052660
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration preoperatively
Trial: NCT03498703
Drug: Azathioprine Pill
RxNorm normalized name: azathioprine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
Trial: NCT03498703
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT01112436
Drug: periarticular injection of multidrug regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
Trial: NCT01436747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 micrograms daily, peroral, 24 weeks
Trial: NCT05288829
Drug: ALXN1210 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Trial: NCT05288829
Drug: ALXN1210 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
Trial: NCT05288829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
Trial: NCT03423329
Drug: Placebo for Brufen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sansovit Syrup
Trial: NCT03558958
Drug: P-188 NF
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer administered daily via sc injection at 5 mg/Kg
Trial: NCT00818415
Drug: Naproxen sodium ER (BAYH6689)
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extented release Naproxen sodium (660mg) administered once a day
Trial: NCT00818415
Drug: Commercial Naproxen (Aleve, BAYH6689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
Trial: NCT00537121
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00537121
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00905905
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Trial: NCT00905905
Drug: Ezetimibe-Simvastatin
RxNorm normalized name: ezetimibe-simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
Trial: NCT00508989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
Trial: NCT00508989
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00472186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will also be administered based on weight.
Trial: NCT00492843
Drug: Ibandronate (Bondronat)
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
Trial: NCT01594177
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
Trial: NCT03765762
Drug: GRF6019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRF6019 for IV infusion
Trial: NCT00054678
Drug: MyoCell™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02053883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
Trial: NCT02656589
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
Trial: NCT00458276
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (i.e., normal saline) for i.v. use.
Trial: NCT00980746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral route
Trial: NCT02432833
Drug: ENVARSUS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
Trial: NCT02432833
Drug: PROGRAF®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf® hard capsules, twice daily, oral formulation
Trial: NCT02432833
Drug: ADVAGRAF®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advagraf® prolonged-release hard capsules, once daily, oral formulation
Trial: NCT00967005
Drug: N Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
Trial: NCT02493946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003664
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01777243
Drug: GSK2315698
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
Trial: NCT03954158
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID regimen
Trial: NCT03954158
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD regimen
Trial: NCT02676323
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.